Pluri (PLUR) said Wednesday that it signed an exclusive collaboration deal with Hemafund, an umbilical cord blood bank, for the distribution and clinical advancement of PLX-R18 cell therapy as a potential treatment for Hematopoietic Acute Radiation Syndrome in Ukraine.
Pluri said it has agreed to produce and supply PLX-R18 and will work with Hemafund to seek funding for the production of an initial 12,000 doses of PLX-R18 to be stored and managed by Hemafund.
The companies plan to sign a separate definitive agreement once the external funding is secured. The collaboration could fetch over $100 million in value for the companies based on the estimated cost and the expected initial stockpile, Pluri said.
The three-year agreement can be extended for three more years, the company said.
Shares of Pluri were up 8.8% in recent Wednesday trading.
Price: 4.69, Change: +0.38, Percent Change: +8.82
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.